
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

For the month of February 2014

Commission File Number 001-16174

**TEVA PHARMACEUTICAL INDUSTRIES
LIMITED**

(Translation of registrant's name into English)

**5 Basel Street, P.O. Box 3190
Petach Tikva 4951033 Israel**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

CONTENTS

At the Special Meeting of Shareholders of Teva Pharmaceutical Industries Limited, which was held on February 24, 2014, the proposal to approve the compensation of Mr. Erez Vigodman, Teva's President and Chief Executive Officer, and matters relating thereto, was approved by the required majority of shareholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Date: February 24, 2014

By: /S/ EYAL DESHEH

Name: **Eyal Desheh**

Title: **Group Executive Vice President, Chief Financial Officer**